Boston Scientific Co. (NYSE:BSX) Shares Acquired by EFG Asset Management North America Corp.

EFG Asset Management North America Corp. raised its holdings in Boston Scientific Co. (NYSE:BSX - Free Report) by 9.2% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 29,930 shares of the medical equipment provider's stock after buying an additional 2,527 shares during the quarter. EFG Asset Management North America Corp.'s holdings in Boston Scientific were worth $2,674,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. TFC Financial Management Inc. raised its stake in shares of Boston Scientific by 308.8% in the fourth quarter. TFC Financial Management Inc. now owns 278 shares of the medical equipment provider's stock worth $25,000 after purchasing an additional 210 shares during the last quarter. Dunhill Financial LLC lifted its stake in Boston Scientific by 86.4% during the 3rd quarter. Dunhill Financial LLC now owns 328 shares of the medical equipment provider's stock valued at $28,000 after acquiring an additional 152 shares during the period. Global Wealth Strategies & Associates boosted its holdings in shares of Boston Scientific by 423.7% in the 4th quarter. Global Wealth Strategies & Associates now owns 309 shares of the medical equipment provider's stock valued at $28,000 after acquiring an additional 250 shares during the last quarter. West Oak Capital LLC purchased a new position in shares of Boston Scientific during the fourth quarter worth $29,000. Finally, Valley National Advisers Inc. raised its holdings in Boston Scientific by 262.4% in the 4th quarter. Valley National Advisers Inc. now owns 395 shares of the medical equipment provider's stock worth $35,000 after purchasing an additional 286 shares during the period. Institutional investors and hedge funds own 89.07% of the company's stock.

Remove Ads

Boston Scientific Price Performance

Shares of BSX traded down $1.51 during trading hours on Friday, reaching $99.29. 7,402,670 shares of the company traded hands, compared to its average volume of 6,051,507. The stock has a fifty day simple moving average of $102.16 and a 200 day simple moving average of $93.11. Boston Scientific Co. has a fifty-two week low of $66.80 and a fifty-two week high of $107.17. The stock has a market capitalization of $146.86 billion, a PE ratio of 79.43, a price-to-earnings-growth ratio of 2.79 and a beta of 0.77. The company has a quick ratio of 1.02, a current ratio of 1.08 and a debt-to-equity ratio of 0.41.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 EPS for the quarter, topping analysts' consensus estimates of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. As a group, research analysts predict that Boston Scientific Co. will post 2.85 EPS for the current fiscal year.

Insider Activity

In other news, EVP Jeffrey B. Mirviss sold 4,675 shares of the firm's stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $104.25, for a total value of $487,368.75. Following the transaction, the executive vice president now directly owns 28,454 shares in the company, valued at approximately $2,966,329.50. This trade represents a 14.11 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP John Bradley Sorenson sold 4,119 shares of Boston Scientific stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $90.02, for a total transaction of $370,792.38. Following the completion of the transaction, the executive vice president now directly owns 35,319 shares of the company's stock, valued at $3,179,416.38. This trade represents a 10.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 137,302 shares of company stock worth $14,319,269. 0.50% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the stock. Citigroup lifted their price target on shares of Boston Scientific from $107.00 to $122.00 and gave the company a "buy" rating in a research note on Thursday, February 6th. JPMorgan Chase & Co. lifted their target price on shares of Boston Scientific from $100.00 to $110.00 and gave the company an "overweight" rating in a research report on Monday, December 16th. UBS Group increased their price objective on Boston Scientific from $105.00 to $130.00 and gave the company a "buy" rating in a research note on Friday, February 7th. StockNews.com cut shares of Boston Scientific from a "buy" rating to a "hold" rating in a research report on Saturday, March 8th. Finally, Barclays lifted their price objective on shares of Boston Scientific from $111.00 to $118.00 and gave the company an "overweight" rating in a report on Monday, February 10th. Two research analysts have rated the stock with a hold rating, twenty-one have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $108.91.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.